Koselugo 25 mg hard capsules, Koselugo 10 mg hard capsules
D1346C00015
Phase 1 small_molecule active
Quick answer
Koselugo 25 mg hard capsules, Koselugo 10 mg hard capsules for Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN) is a Phase 1 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active